The Mainz vaccine manufacturer BioNTech is further expanding its production network in Southeast Asia. There is also progress with the Chinese partner Fosun.

Employee in the BioNTech production facility in Marburg

Dhe Mainz vaccine manufacturer BioNTech is expanding: In Singapore, the biotech company is planning to open a regional headquarters for the Southeast Asia region this year and will also produce there in the future. As the company announced on Monday, a fully integrated production facility for mRNA is to be built in Singapore, which will in future offer capacities for the growing pipeline of vaccine candidates. The Corona-Vakazin, which BioNTech developed together with the American company Pfizer, is also based on mRNA technology.

The Mainz-based company had previously opened an American headquarters in Cambridge in the US state of Massachusetts last year. In addition, the plant in Singapore is to create new production facilities in order to be able to quickly address potential pandemic dangers if necessary, the company said. The new end-to-end mRNA production facility, which is scheduled to go into operation in 2023, will be equipped with state-of-the-art manufacturing processes and a digital infrastructure.

There it should be possible to manufacture a number of new mRNA vaccines and therapeutics against infectious diseases and cancer. The plant is scheduled to be able to produce several hundred million doses a year, depending on the vaccine or product candidate. BioNTech did not name an investment sum.

“Having different nodes in our production network is an important strategic step in expanding our global presence and manufacturing capacity. The planned mRNA production facility will expand our network capacity. It will also help us manufacture and ship our mRNA vaccines and therapeutics to people around the world, ”said BioNTech CEO Ugur Sahin.

BioNTech recently put a former Novartis production facility in Marburg into operation after renovation work and certification procedures, where it is producing the corona vaccine. In the current year alone, BioNTech and its partner Pfizer want to produce a total of 2.5 billion doses of the corona vaccine, and 3 billion doses are planned for the next year.

Meanwhile, BioNTech is also making progress with the Chinese development partner Fosun, with whom the Mainz-based company joined forces in March of last year. Last weekend, Fosun announced that it would set up a joint venture with BioNTech to produce the vaccine. The Chinese pharmaceutical company wants to provide a facility in which up to a billion vaccine doses can be produced annually, the statement said. The two partners expect the vaccine to be approved in China by July at the latest. Separate clinical studies had run there.